targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04123366 | Recruiting | 2 | 2019-11-18 | null | null | null | null | Phase II+ | 1,168,231,105,108 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03239015 | Recruiting | 2 | 2017-01-01 | null | null | null | null | Phase II+ | 1,219,770,712,569 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00782574 | Active, not recruiting | 1 | 2008-11-12 | null | null | null | null | null | 25,769,805,558 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03742895 | Recruiting | 2 | 2018-12-12 | null | null | null | null | Phase II+ | 111,669,149,986 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00819221 | Active, not recruiting | 1 | 2009-01-05 | null | null | null | null | null | 154,618,823,992 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516802 | Completed | 1 | 2007-01-01 | null | null | null | null | null | 154,618,824,204 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01063816 | Completed | 1 | 2010-01-01 | null | null | null | null | null | 171,798,692,513 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03499444 | Active, not recruiting | 1 | 2018-02-06 | null | null | null | null | null | 180,388,626,873 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00777582 | Active, not recruiting | 1 | 2008-10-27 | null | null | null | null | null | 214,748,366,813 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03553108 | Completed | 1 | 2018-05-16 | null | null | null | null | null | 231,928,236,086 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01921140 | Active, not recruiting | 1 | 2013-09-24 | null | null | null | null | null | 455,266,534,629 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04171700 | Recruiting | 2 | 2019-11-21 | null | null | null | null | Phase II+ | 463,856,468,694 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |